unresectable - Robuta Search

https://publires.unicatt.it/it/publications/predicting-early-recurrence-after-resection-of-initially-unresect/ Predicting early recurrence after resection of initially unresectable colorectal liver metastases:... liver metastases predicting early recurrence resection https://my.omnihealthpractice.com/article/nivolumab-ipilimumab-combination-approved-by-fda-as-first-line-treatment-for-unresectable-or-metastatic-hcc/ Nivolumab + ipilimumab combination approved by FDA as first-line treatment for unresectable or... Sep 15, 2025 - In advanced HCC, the tumor microenvironment fosters immune evasion by upregulating inhibitory pathways that suppress cytotoxic T-cell activity. Nivolumab +... first line treatment nivolumab ipilimumab combination approved https://www.laboratoire-cicly.fr/publications/unresectable-peritoneal-metastasis-treated-by-pressurized-intraperitoneal-aerosol-chemotherapy-pipac-leading-to-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy/ Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy... unresectable peritoneal metastasis treated pressurized https://www.cancerdir.com/2018/08/objective-to-judge-novel-hormonal-therapies-in-individuals-with-unresectable-benign/ Objective To judge novel hormonal therapies in individuals with unresectable Benign – High potency... objective judge novel hormonal therapies https://iris.uniupo.it/handle/11579/77367 Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case... imatinib mesylate the treatment large unresectable dermatofibrosarcoma https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-00566&r=1 Intestinal or Multivisceral Transplantation for the Treatment of Unresectable Mucinous Carcinoma... Intestinal or Multivisceral Transplantation for the Treatment of Unresectable Mucinous Carcinoma Peritonei, TRANSCAPE Trial for the mucinous carcinoma intestinal multivisceral transplantation https://horizonnt.ca/trial/living-donor-liver-transplantation-for-unresectable-colorectal-cancer-liver-metastases/ Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases - Horizon... A study on living donor liver transplantation for unresectable colorectal cancer liver metastases. Learn more and see if you qualify today! living donor liver transplantation colorectal cancer unresectable metastases https://pure.lib.cgu.edu.tw/en/publications/concurrent-chemoradiotherapy-for-unresectable-thymic-carcinoma/ Concurrent chemoradiotherapy for unresectable thymic carcinoma - Chang Gung University Academic... chang gung university thymic carcinoma concurrent chemoradiotherapy unresectable https://staging.xpertpatient.com/conversation-guides/liver-cancer-primary-unresectable/ Liver Cancer Primary Unresectable - XpertPatient May 6, 2023 - New to Primary Unresectable Liver Cancer? Understand your Primary Unresectable Liver Cancer and compare your treatment options. liver cancer primary unresectable https://beonemedicines.com/clinical-trials/solid-tumors/phase-3-study-of-tislelizumab-sorafenib-unresectable-hcc-nct03412773/ A Study of Tislelizumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma - NCT03412773 |... Feb 17, 2026 - Learn about the BeOne clinical trial comparing Tislelizumab Versus Sorafenib in participants with Unresectable Hepatocellular Carcinoma (HCC) to improve... a study hepatocellular carcinoma tislelizumab versus sorafenib https://adisinsight.springer.com/trials/700247062?error=cookies_not_supported&code=388da279-d743-499a-81b0-ff77b66f4f33 A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC... This study is investigating the safety of the combined treatments of dabrafenib [Tafinlar], trametinib [Mekinist] and metformin [Glucophage] and then estimate phase i trial dabrafenib trametinib metformin https://ascopost.com/news/october-2021/hepatic-arterial-infusion-of-folfox-vs-transarterial-chemoembolization-for-unresectable-large-hepatocellular-carcinoma/ Hepatic Arterial Infusion of FOLFOX vs Transarterial Chemoembolization for Unresectable Large... In a Chinese phase III trial reported in the Journal of Clinical Oncology, Li et al found that hepatic arterial infusion chemotherapy with FOLFOX... hepatic arterial infusion folfox transarterial chemoembolization unresectable https://air.unipr.it/handle/11381/3040233 Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma hepatocellular carcinoma atezolizumab plus bevacizumab unresectable https://www.takedaoncology.com/newsroom/news-releases/2024/fruzaqla-approval-japan/ Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable... Takeda announces the approval of FRUZAQLA (fruquintinib) by Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable advanced or... in japan the treatment takeda receives approval https://www.themednet.org/what-volumes-do-you-treat-for-unresectable-tracheobronchial-cancer What volumes do you treat for unresectable tracheobronchial cancer? | Mednet Physician discussion: What volumes do you treat for unresectable tracheobronchial cancer?. See expert answers and community insights on Mednet. do you volumes treat unresectable tracheobronchial https://www.curis.com/study/ca-4948-in-combination-with-folfox-pd-1-inhibitor-trastuzumab-for-untreated-unresectable-gastric-and-esophageal-cancer/ CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable... Oct 7, 2026 - This is a phase I trial of CA-4948 in combination with FOLFOX/PD-1 inhibitor with or without trastuzumab for unresectable gastric, GEJ, and esophageal cancer.... combination folfox inhibitor trastuzumab untreated https://www.onclive.com/view/fda-grants-fast-track-designation-to-emactuzumab-for-unresectable-tgct FDA Grants Fast Track Designation to Emactuzumab for Unresectable TGCT | OncLive Oct 5, 2026 - The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor. fast track designation fda grants emactuzumab unresectable